STSA News and Press, Satsuma Pharmaceuticals Inc. From 04/18/20

Generally speaking, small-cap growth stocks probably aren't the first place you'd look to invest in during a particularly turbulent market. Underscoring this point, small caps were hit far harder than their mid- and large-cap peers during the height of the COVID-19-induced sell-off in March. Ho...

Satsuma Pharmaceuticals Inc. (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We had the opportunity to host a virtual fireside chat with the Satsuma Pharmaceuticals management team, including John Kollins (Preside...

Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Satsuma reported better-than expected 4Q19 EPS loss of ($0.62) vs our ($0.79), driven by lower OpEx of $11M vs our $15M. However, we be...

Satsuma Pharmaceuticals (NASDAQ: STSA ): Q4 GAAP EPS of -$0.62 beats by $0.20 . More news on: Satsuma Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial  evaluating STS101 for the acute treatment of migraine Company well-capitalized with cash, cash equivalents, and marketable securities of $117.9 million at the end of 2019, providi...

Facing record-high volatility and market uncertainty, one biotech is scheduled for the week ahead. Formed by New Enterprise Associate's orphan drug accelerator Cydan, genetic disorder biotech Imara (IMRA) plans to raise $76 million at a $301 million market cap. The Boston-based company's sol...

The following slide deck was published by Satsuma Pharmaceuticals, Inc. in conjunction with this Read more ...

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, will present a corporate update at the 9 th  Annual ...

Gainers: Benitec Biopharma (NASDAQ: BNTC )  +51% . More news on: Benitec Biopharma Limited, Assertio Therapeutics, Inc., Ocwen Financial Corporation, Stocks on the move, , Read more ...

AbbVie (NYSE: ABBV ) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket. More news on: AbbVie Inc., Alkermes plc, BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...